---
title: Identify genetic causes of Parkinson
nct_id: NCT05721911
status: RECRUITING
sponsor: IRCCS San Raffaele
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05721911"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05721911"
last_fetched: "2026-05-10T14:06:17.844Z"
source: "Parkinson's Pathways (curated)"
---
# Identify genetic causes of Parkinson

**Goal (in five words):** Identify genetic causes of Parkinson

**Official Title:** Implementing a National Biobank of Genetic, Sporadic and Prodromic Parkinson's Disease With Whole Genome Analysis and Functional Assessment of Polygenic Inheritance by iPSC Technology

**Trial ID:** [NCT05721911](https://clinicaltrials.gov/study/NCT05721911)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** IRCCS San Raffaele
- **Target Enrollment:** 230 participants
- **Start Date:** 2023-10-30
- **Completion Date:** 2026-03-04
- **Conditions:** Parkinson Disease, REM Sleep Behavior Disorder
- **Interventions:** whole genome sequencing
- **Intervention Types:** GENETIC

## Summary For Families

The goal is to build a national biobank linking whole genome data and lab-grown cell models to figure out how combinations of genetic variants influence Parkinson's risk, progression, and the link with REM sleep behavior disorder. Participants give samples for whole genome sequencing to find known and new risk variants and for making induced pluripotent stem cells, which are turned into neurons so researchers can test how a person’s unique polygenic profile alters cell function; the project is observational and does not change your Parkinson's medications. Adults 18 and older are eligible, including people with Parkinson's who have at least two cardinal signs with tremor or bradykinesia and a documented response to L-dopa or dopamine agonists, and people with idiopathic RBD; the study excludes those with dementia, other neurodegenerative diseases, major psychiatric conditions, or prolonged use of certain psychotropic drugs.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria PD patients:

* Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, onset asymmetric) one of which must be tremor or bradykinesia;
* Absence of atypical symptoms such as: i) early postural instability, freezing phenomena, cognitive impairment, hallucinations, pathological involuntary movements, vertical gaze paralysis; ii) confirmed causes of secondary parkinsonism (focal lesions, drugs, substances toxic);
* Documented response to L-dopa or dopamine agonist use (or lack of adequate therapeutic attempt with L-dopa or dopamine agonists).

Inclusion Criteria RBD patients:

• Subjects affected by idiopathic RBD that will be selected according to the most recent criteria international classification of sleep disorders (ICSD-3).

Exclusion Criteria:

* pre-existing psychiatric conditions;
* Neurodegenerative neurological diseases such as multiple sclerosis, lateral sclerosis amyotrophic, Alzheimer's, neuromuscular pathologies, epilepsy;
* diagnosis of dementia;
* depression;
* prolonged intake of anxiolytics, antidepressants, antipsychotics, hypnotic drugs, cognitive stimulants
```

## Locations (1)

- IRCCS San Raffaele, Milan, Italy, Italy _(42.7824, 12.5984)_
  - Vania Broccoli, PhD — (CONTACT) — 0226434616 — broccoli.vania@hsr.it

## Central Contacts

- Vania Broccoli, PhD — (CONTACT) — +39 0226434616 — broccoli.vania@hsr.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT05721911*  
*HTML version: https://parkinsonspathways.com/trial/NCT05721911*  
*Source data: https://clinicaltrials.gov/study/NCT05721911*